J Korean Orthop Assoc.  2010 Apr;45(2):151-154. 10.4055/jkoa.2010.45.2.151.

Osteonecrosis of the Jaw in a Patient with Osteoporosis Treated with Oral Bisphosphonates

• Choi SW
• Kim SR
• Lee KB
• Nam KW
• Seo KB
• Nam U
• Kim HJ

• KMID: 2185584
• DOI: http://doi.org/10.4055/jkoa.2010.45.2.151

Abstract

Bisphosphonates are widely used in the management of metastatic bone disease and in the prevention of osteomalacia and osteoporosis. In particular, oral preparations are more commonly used for the prevension and treatment of osteoporosis. Bisphosphonate-related osteonecrosis of the jaws (BRONJ) has been well documented recently in relation to intravenous preparations of the drug. But, a few cases have been reported of oral bisphosphonate-associated osteonecrosis. We could not find any risedronate cases in the Korean medical literature. Here we report a case of BRONJ in a 91-year-old woman patient receiving an oral bisphosphonate (risedronate) for the treatment of osteoporosis.

Keyword

osteoporosis; osteonecrosis; bisphosphonate

MeSH Terms

Bisphosphonate-Associated Osteonecrosis of the Jaw
Bone Diseases
Diphosphonates
Etidronic Acid
Female
Humans
Jaw
Osteomalacia
Osteonecrosis
Osteoporosis
Risedronate Sodium
Diphosphonates
Etidronic Acid

Figure

• 

  Figure 1 A dental panoramic view demonstrates osseous sclerosis (arrow) and radiolucent lesion with irregular margin (triangle) in left sides of mandible.

• 

  Figure 2 The microscopic finding shows chronic osteomyelitis associated with necrotic bone with empty lacunae and infiltration of numerous inflammatory cells (hematoxylin-eosin stain, original magnification ×100).

Reference

1. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006. 144:753–761.

2. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007. 65:369–376.

3. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the americal society for bone and mineral research. J Bone Miner Res. 2007. 22:1479–1491.

4. Merigo E, Manfredi M, Meleti M, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed. 2006. 77:109–117.

5. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004. 62:527–534.

6. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006. 7:508–514.

7. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007. 29:1548–1558.

8. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005. 90:1294–1301.

9. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American academy of oral medicine position paper. J Am Dent Assoc. 2005. 136:1658–1668.

10. Lam DK, Sándor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc. 2007. 73:417–422.